Arvinas Presents Promising Preclinical Data for BCL6 Degrader ARV-393 in Lymphoma Treatment

Arvinas Inc. (NASDAQ:ARVN) is one of the best low priced pharma stocks to buy now. Earlier on June 13, Arvinas presented encouraging preclinical data for its investigational PROteolysis TArgeting Chimera/PROTAC B-cell lymphoma 6 protein (BCL6) degrader, called ARV-393, at the European Hematology Association/EHA 2025 Congress in Milan, Italy. BCL6 drives B-cell lymphomas.

The studies highlighted ARV-393’s single-agent activity. In a patient-derived xenograft/PDX model of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (nTFHL-AI, also known as AITL), derived from a patient who relapsed post-chemotherapy, ARV-393 substantially reduced tumor burden in the peripheral blood, bone marrow, and spleen.

Arvinas Presents Promising Preclinical Data for BCL6 Degrader ARV-393 in Lymphoma Treatment

A biopharma executive in a meeting room discussing the clinical-stage of a new therapy.

This represents a potential first for preclinical evidence of anti-tumor activity by an efficacious BCL6-targeted small-molecule degrader in a human nTFHL-AI model. Furthermore, ARV-393 monotherapy achieved robust tumor growth inhibition/TGI of at least 95% in two PDX models of transformed follicular lymphoma/tFL.

Arvinas Inc. (NASDAQ:ARVN) is a clinical-stage biotechnology company that discovers, develops, and commercializes therapies to degrade disease-causing proteins.

While we acknowledge the potential of ARVN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ARVN and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.